Bowel cancer incidence set to rise: Research

NewsGuard 100/100 Score

According to the latest research from the Cancer Council, the incidence of bowel cancer in Australia is set to rise to 21,000 cases a year in the next decade. The report shows that one in five cases are diagnosed at an advanced stage, due to a lack of screening. This research is being used to renew the Federal Government’s full funding and implementation of the national bowel cancer screening program. Funding for the program is due to expire at the end of June.

According to Cancer council chief executive, Professor Ian Olver the program needs to be expanded. “The new data shows that we expect a 50 per cent increase in the incidence of bowel cancer over the next ten years…But we can actually do something about that if we reinvigorate the national bowel screening program and complete it.” At present the national screening program targets people turning 50, 55 and 65, despite expert recommendations that everyone over 50 should be screened. “The figures about saving 20 to 30 lives per week in Australia, depend not on one-off testing, but testing everyone 50 and above every 2 years,” he said.

Professor Olver added that lifestyle as well as population trends would drive the increase, and it underscored the need for an effective means to combat the disease. “The ageing of the population is one issue, because bowel cancer does increase with increasing age…Obesity is also a risk factor for bowel cancer, so those two are major problems that will impact on the incidence over the next decade,” he explained.

“The thing about bowel cancer screening is, because a polyp precedes cancer, you can pick up a polyp before it becomes cancerous and deal with it so a person never gets cancer…We calculate that with a fully implemented bowel screening program, you're saving between 20 and 30 lives per week…It is also cost effective ... by not having to treat as much metastatic disease, which is expensive to treat, and by reducing the number of colonoscopies that are being used as a primary screen,” he explained about the screening program. Prof Olver said the expanded program could cost about $150 million a year, but taking healthcare savings into account would cut this figure by about two thirds.

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2018, August 23). Bowel cancer incidence set to rise: Research. News-Medical. Retrieved on May 26, 2024 from https://www.news-medical.net/news/20110321/Bowel-cancer-incidence-set-to-rise-Research.aspx.

  • MLA

    Mandal, Ananya. "Bowel cancer incidence set to rise: Research". News-Medical. 26 May 2024. <https://www.news-medical.net/news/20110321/Bowel-cancer-incidence-set-to-rise-Research.aspx>.

  • Chicago

    Mandal, Ananya. "Bowel cancer incidence set to rise: Research". News-Medical. https://www.news-medical.net/news/20110321/Bowel-cancer-incidence-set-to-rise-Research.aspx. (accessed May 26, 2024).

  • Harvard

    Mandal, Ananya. 2018. Bowel cancer incidence set to rise: Research. News-Medical, viewed 26 May 2024, https://www.news-medical.net/news/20110321/Bowel-cancer-incidence-set-to-rise-Research.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
POSTECH and ImmunoBiome make significant breakthrough in the fight against cancer